Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

187.00DKK
8:44am EDT
Price Change (% chg)

kr.-3.00 (-1.58%)
Prev Close
kr.190.00
Open
kr.191.50
Day's High
kr.192.00
Day's Low
kr.185.00
Volume
103,452
Avg. Vol
192,024
52-wk High
kr.204.50
52-wk Low
kr.65.50

BAVA.CO

Chart for BAVA.CO

About

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate... (more)

Overall

Beta: 1.41
Market Cap (Mil.): kr.4,961.44
Shares Outstanding (Mil.): 26.11
Dividend: --
Yield (%): --

Financials

  BAVA.CO Industry Sector
P/E (TTM): -- 33.07 34.41
EPS (TTM): -2.35 -- --
ROI: -5.93 18.03 17.37
ROE: -6.49 18.69 18.18
Search Stocks

BRIEF-Bavarian Nordic increases its share capital by nominally DKK 13,319,840

* Capital increase in Bavarian Nordic A/S as a result of completion of a Direct Placement to Johnson & Johnson Development Corporation

29 Oct 2014

BRIEF-Bavarian Nordic to expand collaboration with Janssen

COPENHAGEN, Oct 23 - Danish biotech company Bavarian Nordic A/S said late on Wednesday: ** it has agreed with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to expand the collaboration announced earlier on Wednesday to include evaluation of Bavarian Nordic's proprietary vaccine platform technology, MVA-BN, for additional undisclosed disease targets. ** Bavarian Nordic and Janssen will collaborate on the evaluation of MVA-BN for three additiona

23 Oct 2014

UPDATE 6-Drugmakers to join forces to make millions of Ebola vaccine doses

* GlaxoSmithKline sees first vaccine doses ready this year

22 Oct 2014

J&J and Bavarian Nordic expand production of an Ebola vaccine program

- Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

22 Oct 2014

J&J and Bavarian Nordic expand production of an Ebola vaccine program

Oct 22 - Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

22 Oct 2014

BRIEF-Bavarian Nordic enters licensing and supply agreement with Janssen on MVA-BN Ebola Vaccine

* Bavarian Nordic enters licensing and supply agreement with Janssen on MVA-BN Ebola Vaccine

22 Oct 2014

BRIEF-Bavarian Nordic in negotiations on manufacturing agreement on its ebola vaccine candidates

* Says company is now in advanced negotiations with a pharmaceutical company on a licensing and manufacturing agreement on its ebola vaccine candidates

22 Oct 2014

NORDIC STOCKS - Factors to watch on Oct 13

HELSINKI, Oct 13 - The following stocks may be affected by company statements, media reports and other factors on Monday:

13 Oct 2014

J&J Ebola vaccine to start clinical trials in early 2015

Sept 4 - Scientists will fast-track tests on another Ebola vaccine, this time from Johnson & Johnson JNJ.N, in another sign that the world's worst outbreak of the virus is mobilizing research into the deadly disease.

04 Sep 2014

Bavarian Nordic sole bidder for Canadian smallpox vaccine supply

COPENHAGEN - Danish biotech company Bavarian Nordic is the only company invited to bid for a tender to supply Canada with smallpox vaccines, a document published August 5 on the Canadian government's web site showed.

06 Aug 2014

Earnings vs. Estimates

Search Stocks